Stocks · News reference

MapLight Therapeutics shares are trading lower after the company announced the 2 ZEPHYR trial's 330/6 mg once-daily dose missed its primary endpoint.

Jul 27, 2026, 1:00 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

SEC EDGARAug 13, 2026, 8:51 PMSEC EDGAR
8-K filing — MapLight Therapeutics, Inc. (MPLT)
Filed: 2026-08-13 AccNo: 0001193125-26-349490 Size: 4 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.02: Results of Operations and Financial Condition Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgar
MPLT
BenzingaAug 13, 2026, 8:27 PMBenzinga Newsdesk
MapLight Therapeutics Q2 EPS $(1.32) Beats $(1.35) Estimate
Read original at benzinga
MPLT
BenzingaAug 13, 2026, 1:12 PMBenzinga Newsdesk
MapLight Therapeutics Enters Securities Purchase Agreement For $150M Private Placement Financing
MapLight Therapeutics, Inc. (NASDAQ:MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, announced today that it has
Read original at benzinga
MPLT
BenzingaAug 10, 2026, 7:51 PMBenzinga Newsdesk
UBS Downgrades MapLight Therapeutics to Neutral, Lowers Price Target to $13
UBS analyst Ashwani Verma downgrades MapLight Therapeutics (NASDAQ:MPLT) from Buy to Neutral and lowers the price target from $52 to $13.
Read original at benzinga
MPLT